We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+2.14%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.51B
AUM Growth
-$1.16B
Cap. Flow
+$107M
Cap. Flow %
1.43%
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$165M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$119M
3
ACLX
Arcellx
ACLX
+$80.8M
4
KURA icon
Kura Oncology
KURA
+$64M
5
JANX icon
Janux Therapeutics
JANX
+$63.5M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$230M
2
VRNA
Verona Pharma
VRNA
+$122M
3
EVH icon
Evolent Health
EVH
+$86.8M
4
CGON icon
CG Oncology
CGON
+$52.7M
5
RXRX icon
Recursion Pharmaceuticals
RXRX
+$51.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.36%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$1.39B 18.53%
10,112,744
+402,316
+4% +$52.9M
PCVX icon
2
Vaxcyte
PCVX
$7.65B
$711M 9.47%
8,689,190
– –
JANX icon
3
Janux Therapeutics
JANX
$912M
$555M 7.39%
10,365,652
+1,200,000
+13% +$63.5M
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.31B
$341M 4.53%
6,084,412
– –
LEGN icon
5
Legend Biotech
LEGN
$3.65B
$244M 3.25%
7,506,934
– –
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.28B
$238M 3.17%
8,909,091
– –
NAMS icon
7
NewAmsterdam Pharma
NAMS
$3.26B
$227M 3.03%
8,845,000
+781,000
+10% +$16.6M
WVE icon
8
Wave Life Sciences
WVE
$1.12B
$225M 3%
18,202,009
– –
ACLX
9
DELISTED
Arcellx
ACLX
$214M 2.84%
2,787,327
+935,848
+51% +$80.8M
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$183M 2.44%
6,300,408
– –
SEPN
11
Septerna Inc
SEPN
$1.51B
$160M 2.13%
+6,995,858
New +$165M
DYN icon
12
Dyne Therapeutics
DYN
$4.68B
$150M 2%
6,381,144
– –
TYRA icon
13
Tyra Biosciences
TYRA
$1.85B
$148M 1.97%
10,637,290
+220,681
+2% +$4M
RXST icon
14
RxSight
RXST
$254M
$129M 1.71%
3,743,018
-173,807
-4% -$7.84M
BCAX
15
Bicara Therapeutics
BCAX
$1.7B
$121M 1.61%
6,955,993
– –
LENZ
16
LENZ Therapeutics
LENZ
$179M
$121M 1.61%
4,178,823
– –
SPRY icon
17
ARS Pharmaceuticals
SPRY
$579M
$115M 1.52%
10,860,977
– –
ETNB
18
DELISTED
89bio
ETNB
$111M 1.48%
14,175,398
– –
XBI icon
19
State Street SPDR S&P Biotech ETF
XBI
$10B
$111M 1.47%
+1,228,240
New +$119M
GERN icon
20
Geron
GERN
$898M
$106M 1.41%
30,009,536
-2,276,219
-7% -$9.09M
ARTV
21
Artiva Biotherapeutics
ARTV
$487M
$99.3M 1.32%
9,853,302
– –
AXSM icon
22
Axsome Therapeutics
AXSM
$11.7B
$84.6M 1.13%
1,000,000
– –
VRNA
23
DELISTED
Verona Pharma
VRNA
$82.1M 1.09%
1,766,830
-3,242,823
-65% -$122M
DAWN
24
DELISTED
Day One Biopharmaceuticals
DAWN
$72.9M 0.97%
5,755,577
-2,116,144
-27% -$29.4M
APGE icon
25
Apogee Therapeutics
APGE
$10.1B
$71.1M 0.95%
1,569,491
-392,372
-20% -$20M
1
2 3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, RA Capital Management held 98 positions worth $7.51B, down 13% from $8.67B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

RA Capital Management's Q4 2024 filing shows 17 new, 9 increased, 16 reduced and 9 closed positions. Its largest new stake was Septerna Inc: 6,995,858 shares worth $160M. The largest sale was Biogen, an estimated $230M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q4 2024 buy was Septerna Inc: 6,995,858 shares worth $160M.
  • RA Capital Management added most to Arcellx in Q4 2024, an estimated $80.8M increase.
  • RA Capital Management's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $122M.
  • RA Capital Management fully exited Biogen in Q4 2024, selling an estimated $230M.
  • RA Capital Management's ten largest holdings make up 58% of its $7.51B portfolio in Q4 2024.
  • RA Capital Management opened 17 new positions and closed 9 in Q4 2024.
  • RA Capital Management's portfolio value fell 13% quarter-over-quarter to $7.51B.

Based on RA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.